Filter results

Clinical Studies

Closed for Enrollment

  • E3A06, Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma Rochester, Minn., Scottsdale/Phoenix, Ariz.

    This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient.

  • Myeloma Referral Study (Race, Ethnicity, and Familial Etiologic Relationship, Risk Association, and Linkage Study) Rochester, Minn.

    The goal of the present study is to answer the question of whether there are clinically relevant subtypes of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) that are associated with populations at high risk for developing these conditions using an online survey and submission of de-identified medical information.

  • Plasmapheresis in Patients With Gammopathies Rochester, Minn.

    This study is being done to obtain blood from patients with gammopathies (the presence of abnormal proteins in the blood). The study doctors wish to test this blood to gain more information about the causes of gammopathy.

  • Risk Factors Associated with Clustered Plasma Cell Dyscrasias in Minnesota Rochester, Minn.

    The purpose of this study is to describe a serial of clustered plasma cell dyscrasia cases in northern Minnesota by describing the disease characteristics, including disease presentations, treatments, and outcomes.  To describe the familial and geographic relationships between clustered plasma cell dyscrasia cases and the common environmental exposures.  Identify the association between exposure and plasma cell dyscrasia development

.